Allotera Therapeutics (Formerly Wugen) Closes $35 Million Financing to Advance Off-the-Shelf CAR-T Therapies for T-Cell Cancers
Allotera Therapeutics closed a $35 million financing round to advance its lead CAR-T therapy, Sofi-cel, with venture debt provided by Banc of California. The financing brings the total Series C capital raised by Allotera to $150 million and will support the global pivotal trial for relapsed or refractory T-cell acute lymphoblastic leukemia.
Key figures
- Total series c raised
- $150 million
- Financing round amount
- $35 million
- Banc of california assets
- $34 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.